Clinical Trial

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 （a PD-L1/CTLA-4 targeted bispecific antibody）.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-02.
Trial Details
NCT Number NCT05985707
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer
Enrollment 80 participants
Start Date 2023-08-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-21